A Plus Biotech (6918) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 愛派司

A Plus Biotech (6918) reported revenue of NT$81.1 million for Oct 2026, +29.8% year on year and +2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$785.6 million (+14.9% year on year).

Year-on-year revenue growth: 10 months in a row. →

In Oct 2026, it ranked No. 86 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$67.2 million24/10Nov 2024 NT$64.2 millionDec 2024 NT$73.1 millionJan 2025 NT$63.2 millionFeb 2025 NT$69.7 million25/02Mar 2025 NT$63.5 millionApr 2025 NT$75.9 millionMay 2025 NT$62 millionJun 2025 NT$76 million25/06Jul 2025 NT$71.6 millionAug 2025 NT$69 millionSep 2025 NT$70.1 millionOct 2025 NT$62.5 million25/10Nov 2025 NT$80.4 millionDec 2025 NT$72 millionJan 2026 NT$71.4 millionFeb 2026 NT$74.2 million26/02Mar 2026 NT$73.8 millionApr 2026 NT$84.9 millionMay 2026 NT$78.9 millionJun 2026 NT$79.2 million26/06Jul 2026 NT$86 millionAug 2026 NT$76.6 millionSep 2026 NT$79.5 millionOct 2026 NT$81.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$81.1 million+29.8%+2.0%
Sep 2026NT$79.5 million+13.4%+3.8%
Aug 2026NT$76.6 million+11.0%-11.0%
Jul 2026NT$86 million+20.1%+8.6%
Jun 2026NT$79.2 million+4.2%+0.4%
May 2026NT$78.9 million+27.2%-7.1%
Apr 2026NT$84.9 million+11.9%+15.1%
Mar 2026NT$73.8 million+16.2%-0.6%
Feb 2026NT$74.2 million+6.5%+4.0%
Jan 2026NT$71.4 million+13.0%-0.9%
Dec 2025NT$72 million-1.5%-10.4%
Nov 2025NT$80.4 million+25.1%+28.6%
Oct 2025NT$62.5 million-7.0%-10.9%
Sep 2025NT$70.1 million+4.9%+1.6%
Aug 2025NT$69 million+2.2%-3.7%
Jul 2025NT$71.6 million+8.6%-5.8%
Jun 2025NT$76 million+24.0%+22.6%
May 2025NT$62 million+5.7%-18.3%
Apr 2025NT$75.9 million+13.5%+19.5%
Mar 2025NT$63.5 million-0.1%-8.9%
Feb 2025NT$69.7 million+30.8%+10.2%
Jan 2025NT$63.2 million+3.4%-13.5%
Dec 2024NT$73.1 million+16.4%+13.8%
Nov 2024NT$64.2 million+11.2%-4.4%
Oct 2024NT$67.2 million+27.8%+0.5%

Jan–Oct 2026 cumulative: NT$785.6 million (+14.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: A Plus Biotech vs PEC / A Plus Biotech vs Lotus Pharm / A Plus Biotech vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16